Hedgehog inhibition promotes a switch from Type II to Type I cell death receptor signaling in cancer cells
Related Experiment Video
Updated: Jun 2, 2026

Quantitative PCR-based Assay to Measure Sonic Hedgehog Signaling in Cellular Model of Ciliogenesis
Published on: January 31, 2025
Satoshi Kurita1, Justin L Mott, Sophie C Cazanave
1Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, United States of America.
Abstract:
TRAIL is a promising therapeutic agent for human malignancies. TRAIL often requires mitochondrial dysfunction, referred to as the Type II death receptor pathway, to promote cytotoxicity. However, numerous malignant cells are TRAIL resistant due to inhibition of this mitochondrial pathway. Using cholangiocarcinoma cells as a model of TRAIL resistance, we found that Hedgehog signaling blockade sensitized these cancer cells to TRAIL cytotoxicity independent of mitochondrial dysfunction, referred to as Type I death receptor signaling. This switch in TRAIL requirement from Type II to Type I death receptor signaling was demonstrated by the lack of functional dependence on Bid/Bim and Bax/Bak, proapoptotic components of the mitochondrial pathway. Hedgehog signaling modulated expression of X-linked inhibitor of apoptosis (XIAP), which serves to repress the Type I death receptor pathway. siRNA targeted knockdown of XIAP mimics sensitization to mitochondria-independent TRAIL killing achieved by Hedgehog inhibition. Regulation of XIAP expression by Hedgehog signaling is mediated by the glioma-associated oncogene 2 (GLI2), a downstream transcription factor of Hedgehog. In conclusion, these data provide additional mechanisms modulating cell death by TRAIL and suggest Hedgehog inhibition as a therapeutic approach for TRAIL-resistant neoplasms.
Insights
Hedgehog signaling blockade sensitizes resistant cancer cells to TRAIL therapy by shifting cell death signaling. This approach bypasses mitochondrial pathways, offering a new strategy for treating TRAIL-resistant neoplasms.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) shows promise for cancer treatment.
- TRAIL-induced cancer cell death often relies on mitochondrial pathways (Type II), but resistance emerges via mitochondrial pathway inhibition.
- Malignant cells can be resistant to TRAIL due to these mitochondrial pathway disruptions.
Purpose of the Study:
- To investigate mechanisms of TRAIL resistance in cholangiocarcinoma.
- To determine if targeting Hedgehog signaling can overcome TRAIL resistance.
- To elucidate the signaling pathways involved in TRAIL sensitization.
Main Methods:
- Utilized cholangiocarcinoma cells as a model for TRAIL resistance.
- Investigated the role of Hedgehog signaling blockade in TRAIL-induced cytotoxicity.
- Assessed the dependence on mitochondrial pathway components (Bid/Bim, Bax/Bak) and Type I death receptor signaling.
- Examined the modulation of X-linked inhibitor of apoptosis (XIAP) expression by Hedgehog signaling.
- Employed siRNA to knockdown XIAP and assess its effect on TRAIL sensitivity.
- Investigated the role of glioma-associated oncogene 2 (GLI2) in regulating XIAP.
Main Results:
- Hedgehog signaling blockade sensitized TRAIL-resistant cholangiocarcinoma cells to TRAIL.
- Sensitization occurred independently of mitochondrial dysfunction, indicating a switch to Type I death receptor signaling.
- This switch was confirmed by the lack of dependence on Bid/Bim and Bax/Bak.
- Hedgehog signaling was found to modulate XIAP expression, a repressor of the Type I pathway.
- XIAP knockdown mimicked the sensitization effect of Hedgehog inhibition.
- Glioma-associated oncogene 2 (GLI2) was identified as the mediator of Hedgehog signaling's regulation of XIAP.
Conclusions:
- Hedgehog signaling blockade offers a novel therapeutic strategy to overcome TRAIL resistance in cancer.
- The mechanism involves a switch from TRAIL-dependent Type II to Type I death receptor signaling.
- Modulation of XIAP by Hedgehog signaling, via GLI2, is a key factor in this sensitization process.
- These findings provide new insights into TRAIL-mediated cell death and suggest therapeutic avenues for resistant cancers.
Related Concept Videos
Hedgehog Signaling Pathway
Hedgehog Signaling Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
The Intrinsic Apoptotic Pathway
Role Of Notch Signalling In Intestinal Stem Cell Renewal
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...

